The Norwegian Financial Supervisory Authority has approved the prospectus dated 3 April 2013 in connection with the listing of 12,923,496 new shares on Oslo Axess.
The prospectus will be made publicly available at the offices of Hofseth BioCare ASA, Smuget 1, 1383 Asker and telephone: +47 66 76 55 60 or +47 66 76 55 62, or one of the Managers. The prospectus will also be available on the following websites:
- Hofseth BioCare ASA, www.hofsethbiocare.no
- Swedbank First Securities, www.swedbank.no
- Norne Securities AS, www.norne.no
For further information, please contact:
Jon Olav Ødegård, CEO Hofseth BioCare ASA
Tel +47 936 32 966
E-mail: joo@h-bc.no
Øystein Omvik, CFO Hofseth BioCare ASA
Tel: +47 936 99 400
E-mail: oystein.omvik@h-bc.no
About Hofseth BioCare:
Hofseth BioCare is a Norwegian biomarine company with the key objective to provide high value added biomarine ingredients for human applications. The Company is founded on the core value of sustainability and optimal use of natural resources. Through innovative production technology and logistics, Hofseth BioCare is able to preserve the quality of protein, calcium and oil extracted from fish off-cuts. Products that previously could only be used as animal feed can now be made suitable for human consumption. HBCs objective is thus to contribute to efficient use of marine resources and entering the higher profit market of quality ingredients for human applications.
This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.